URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies.

As of 06/30/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  Israel
IPO date:  05/04/2017
Outstanding shares:  22,693,170
Average volume:  267,898
Market cap:   $181,091,497
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BZ7PJQ1
Valuation   (See tab for details)
PE ratio:   -1.56
PB ratio:   20.83
PS ratio:   6.09
Return on equity:   663.45%
Net income %:   -380.92%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy